Policy / Regulatory

China Orders Whole‑Class Listing of "Orphine‑Type Substances" in Non‑Medicinal Narcotic and Psychotropic Catalogue – Tri‑Agency Control Takes Effect 1 October 2026
NHC (NHFPC)NMPA

China Orders Whole‑Class Listing of “Orphine‑Type Substances” in Non‑Medicinal Narcotic and Psychotropic Catalogue – Tri‑Agency Control Takes Effect 1 October 2026

China's Ministry of Public Security (MPS), the National Health Commission (NHC), and the National Medical Products Administration (NMPA) jointly issued an announcement deciding to list the entire class of "orphine‑type…

NMPA Releases 109th RLD Catalog for Chemical Generics – 30 New Product Specifications Added, 24 Supplemented

NMPA Releases 109th RLD Catalog for Chemical Generics – 30 New Product Specifications Added, 24 Supplemented

US Treasury Drafts China Pharma Investment Rules Likely to Preserve Licensing Deals – A Carve‑Out From Broader National‑Security Tightening

US Treasury Drafts China Pharma Investment Rules Likely to Preserve Licensing Deals – A Carve‑Out From Broader National‑Security Tightening

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Shanghai Unveils Action Plan and Fund for Biopharma M&A Activities
Finance

Shanghai Unveils Action Plan and Fund for Biopharma M&A Activities

Beijing Expands Medical Insurance Sharing to Near Relatives with New Policy
BMI

Beijing Expands Medical Insurance Sharing to Near Relatives with New Policy

CDE Releases 89th Batch of Reference Preparations for Generic Quality Consistency
CDEGQCE testing

CDE Releases 89th Batch of Reference Preparations for Generic Quality Consistency

NMPA Proposes Draft for Simplified Registration of Traditional Chinese Medicines from Hong Kong and Macao
NMPA

NMPA Proposes Draft for Simplified Registration of Traditional Chinese Medicines from Hong Kong and Macao

Show More